<DOC>
	<DOCNO>NCT01875003</DOCNO>
	<brief_summary>This randomize , multicenter , double-blind , placebo-controlled , parallel-group study evaluate efficacy , safety , tolerability lebrikizumab adolescent participant asthma whose disease remain uncontrolled despite daily treatment inhaled corticosteroid ( ICS ) therapy least one second controller medication . Participants randomize 1:1:1 ratio receive double-blind treatment either lebrikizumab ( 'High ' 'Low ' ) placebo , administer subcutaneous ( SC ) every 4 week ( Q4W ) 52 week , addition standard-of-care therapy . This follow optional 52-week double-blind active-treatment extension . The anticipated time study treatment 104 week . Participants complete study Week 104 , discontinue prematurely decide take part optional active-treatment extension transition 20-week safety follow-up period .</brief_summary>
	<brief_title>A Study Lebrikizumab Adolescent Participants With Uncontrolled Asthma Who Are Inhaled Corticosteroids Second Controller Medication</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Asthma diagnosis great equal ( &gt; /= ) 12 month prior Visit 1 Bronchodilator response screen Prebronchodilator FEV1 40 percent ( % ) 90 % predict Visits 2 3 On high dose ICS therapy &gt; /= 6 month prior Visit 1 On eligible second controller medication 6 month prior Visit 1 Uncontrolled asthma define protocol screen time randomization Demonstrated adherence controller medication screen period History severe allergic reaction anaphylactic reaction biologic agent know hypersensitivity component lebrikizumab injection Maintenance oral corticosteroid therapy within 3 month prior Visit 1 Treatment systemic ( oral , intravenous [ IV ] , intramuscular [ IM ] ) corticosteroid within 4 week prior Visit 1 screen period Treatment intraarticular corticosteroid within 4 week prior Visit 1 screen period anticipate need intraarticular corticosteroid course study Infection meet follow criterion : Any infection require hospital admission require treatment IV IM antibiotic within 4 week prior Visit 1 screening ; active infection require treatment oral antibiotic within 2 week prior Visit 1 screening ; upper low respiratory tract infection within 4 week prior Visit 1 screening ; active parasitic infection Listeria monocytogenes infection within 6 month prior Visit 1 screen History active tuberculosis require treatment Known immunodeficiency , include , limited , human immunodeficiency virus ( HIV ) infection Evidence acute chronic hepatitis know liver cirrhosis History cystic fibrosis , bronchiectasis , and/or clinically significant lung disease asthma Diagnosis history malignancy current evaluation potential malignancy Current smoker former smoker history great ( &gt; ) 10 packyears History alcohol drug abuse Past and/or current use anti interleukin ( IL ) 13 antiIL4/IL13 therapy , include lebrikizumab Use monoclonal antibody therapy , include omalizumab , within 6 month 5 drug halflives ( whichever longer ) prior Visit 1 Initiation change allergen immunotherapy within 3 month prior Visit 1 screen History bronchial thermoplasty</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>